Clinical research
The company’s shares exploded 300% in after-hours trading yesterday at the news, giving the company a market value of $469.6 million.
Prokarium, a private biotechnology company developing vaccines against infectious diseases and immunotherapy for solid tumors, has received Clinical Trial Authorization acceptance from the UK Medicines and Healthcare products Regulatory Agency to run a first-in-human Phase I trial with Entervax™, a bivalent vaccine against enteric fever.
Vaccitech progresses clinical development of Universal Influenza A Vaccine (VTP-100) in Belgium and Australia and expects top-line data in early 2020
Safety and efficacy evaluation will be performed on 36 patients from 3 hospitals located in US and Australia
Tecentriq is the company’s PD-L1 checkpoint inhibitor. Avastin is an antibody that binds to VEGF and interferes with tumor blood supply.
The drug combination did not hit the co-primary endpoint of recurrence-free survival in patients whose tumors expressed PD-L1 greater than 1%.
KidneyX seeks breakthrough solutions to transform kidney care
Frontage Clinical Services Inc. announced the implementation of ClinSpark®, a web-based eSource platform, that supports activities from subject recruitment through database lock.
Amidst rumors that Novartis might be interested in an acquisition, The Medicines Company announced data from ORION-10, the second of three 19-month Phase III trials of inclisiran for lowering cholesterol.
Myovant announced that its Phase III HERO trial relugolix met its primary endpoint and six key secondary endpoints in advanced prostate cancer.
PRESS RELEASES